Zhanzhan Y. Feng

Cancer Center And State Key Laboratory Of Biotherapy
Chengdu, 610041, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 26 publications

Novel FGFR Inhibitor Combined with Radiotherapy Induces GSDME-Dependent Pyroptosis to Amplify Immunogenic Cell Death Improving Anti-Tumor Activity.

Novel FGFR Inhibitor Combined with Radiotherapy Induces GSDME-Dependent Pyroptosis to Amplify Immunogenic Cell Death Improving Anti-Tumor Activity.

Journal: Journal of medicinal chemistry

Published: December 30, 2025

ROS-sensitive nanocarriers for synergistic X-PDT/chemo/immunotherapy of triple-negative breast cancer and metastasis.

ROS-sensitive nanocarriers for synergistic X-PDT/chemo/immunotherapy of triple-negative breast cancer and metastasis.

Journal: Acta biomaterialia

Published: August 07, 2025

Discovery of Novel Proteolysis-Targeting Chimera Molecules as Degraders of Programmed Cell Death-Ligand 1 for Breast Cancer Therapy.

Discovery of Novel Proteolysis-Targeting Chimera Molecules as Degraders of Programmed Cell Death-Ligand 1 for Breast Cancer Therapy.

Journal: Journal of medicinal chemistry

Published: June 18, 2024

Synthesis and identification of a selective FGFR2 degrader with potent antiproliferative effects in gastric cancer.

Synthesis and identification of a selective FGFR2 degrader with potent antiproliferative effects in gastric cancer.

Journal: European journal of medicinal chemistry

Published: June 07, 2024

Novel Amphiphilic PROTAC with Enhanced Pharmacokinetic Properties for ALK Protein Degradation.

Novel Amphiphilic PROTAC with Enhanced Pharmacokinetic Properties for ALK Protein Degradation.

Journal: Journal of medicinal chemistry

Published: June 05, 2024

A novel selective FAK inhibitor E2 inhibits ovarian cancer metastasis and growth by inducing cytotoxic autophagy.

A novel selective FAK inhibitor E2 inhibits ovarian cancer metastasis and growth by inducing cytotoxic autophagy.

Journal: Biochemical pharmacology

Published: March 12, 2024

A novel VEGFR inhibitor ZLF-095 with potent antitumor activity and low toxicity.

A novel VEGFR inhibitor ZLF-095 with potent antitumor activity and low toxicity.

Journal: Heliyon

Published: December 14, 2022

Design and Synthesis of Fibroblast Growth Factor Receptor (FGFR) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Cancer.

Design and Synthesis of Fibroblast Growth Factor Receptor (FGFR) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Cancer.

Journal: Journal of medicinal chemistry

Published: November 30, 2022

Discovery of the GSH responsive "Y-PROTACs" targeting ALK and CDK4/6 as a potential treatment for cancer.

Discovery of the GSH responsive "Y-PROTACs" targeting ALK and CDK4/6 as a potential treatment for cancer.

Journal: European journal of medicinal chemistry

Published: October 21, 2022

Design, synthesis and biological evaluation of 7-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-2,3-dihydro-1H-inden-1-one derivatives as potent FAK inhibitors for the treatment of ovarian cancer.

Design, synthesis and biological evaluation of 7-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-2,3-dihydro-1H-inden-1-one derivatives as potent FAK inhibitors for the treatment of ovarian cancer.

Journal: European journal of medicinal chemistry

Published: August 25, 2021

Design, synthesis and biological evaluations of a series of Pyrido[1,2-a]pyrimidinone derivatives as novel selective FGFR inhibitors.

Design, synthesis and biological evaluations of a series of Pyrido[1,2-a]pyrimidinone derivatives as novel selective FGFR inhibitors.

Journal: European journal of medicinal chemistry

Published: February 03, 2021

Gamma-Ray Observation of the Cygnus Region in the 100-TeV Energy Region.

Gamma-Ray Observation of the Cygnus Region in the 100-TeV Energy Region.

Journal: Physical review letters

Published: January 26, 2021

Showing 1-12 of 26

Last Updated: 09/26/2026